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Introduction
Diagnostics play an important role in uncovering the symptoms and 
signs shown by patients. It can implicate the onset of a disease and also 
predict the different stages of that disease. In order to establish accurate 
prognosis, patients need to undergo a wide array of tests ranging from 
blood and urinary analysis to X-ray and magnetic resonance imaging 
(MRI). These tests often depend on immune inflammatory activated 
factors such as leukocyte counts, red blood cell sedimentation rate, 
cytokines and protein accumulation. In addition, imaging systems can 
only detect changes in the structure and morphology of organs but fail 
to stipulate a definite diagnosis. 
One of the major setbacks in developing effective treatments against 
chronic diseases is the multi-drug resistant (MDR) phenomenon. 
Examples of such occurrences include the resistance of Enterococci 
to Vancomycin (VRE) [1] and Methicillin-Resistant Staphylococcus 
aureus [2] or the enhanced efflux of drugs due to increased transport 
pumps like P-glycoproteins (P-gp) [3]. Therefore, for a treatment to 
be optimum it needs to satisfy key requirements. These include the 
ability to diagnose diseases at an early stage, image the accurate site of 
infections, be specific enough to discriminate between the diseased and 
healthy cells and more importantly be effective and safe even with long 
term usage. This review discusses the recent therapeutic advances of 
the natural bioactive protein, lactoferrin (Lf) with regards to infection 
and cancer, its role as a diagnostic and the current nano-based findings 
on the use of Lf as a potential treatment agent.
Lactoferrin 
Since its first isolation from bovine milk more than 70 years ago 
[4] and its purification and sequencing from both bovine and human 
milk almost 40 years later [5], Lf, also known as lactotransferrin, has 
caused a significant uproar in the field of cancer research. Primarily, 
it is an iron binding glycoprotein with a structure and size that closely 
resembles (60% sequence homology) to another iron-transporting 
family, the transferrins (Tf) [6]. The regulation of Lf is not only 
restricted to milk, in fact its production occurs in a wide range of 
secretory fluids including saliva, tears, the reproductive system and 
in renal organs [7]. Lower concentrations are found in plasma, bile 
fluids, mucosal secretions, pancreatic fluids and in neutrophils cells [8]. 
Structurally, Lf weighs approximately 80kDa and the polypeptide folds 
into two globular lobes. Each globe contains two major domains. These 
domains serve as the binding and glycosylation sites for iron molecules 
and carbonate ions. Apart from iron, Lf binds to an array of metal ions 
(to a much lower affinity). These include gallium, aluminium, zinc, 
manganese, cobalt, copper and lanthanides. Further, depending on 
the amount of binding, Lf can be classified as apo-Lf (iron depleted), 
monoferric Lf (one ferric ion) and holo-Lf (two ferric ions) [9]. 
Roles played by lactoferrin
In addition to its role in iron transporting, various other functions, 
ranging from anti-viral to anti-carcinogenic, has intrigued the 
curiosity of many researchers. Recent progress in our understanding 
of the mechanisms of Lf has led us to believe that this protein activates 
intracellular signalling, specifically through the modulation of 
cytokines, chemokines, growth factors and interleukins. Consequently, 
inflammatory diseases and tumour progression depends primarily on 
the dysfunction of these factors and the activation of immune cells such 
as T lymphocytes, monocytes and natural killer (NK) cells. Therefore, 
studying the possible influences Lf may exert on regulating these 
mediators is beneficial. 
Metabolism and absorption of iron
Iron is a crucial element required for most biological and cellular 
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Abstract
Lactoferrin (Lf) is a natural occurring iron binding protein present in many mammalian excretions and involved 
in various physiological processes. Lf is used in the transport of iron along with other molecules and ions from the 
digestive system. However its the modulatory functions exhibited by Lf in connection to immune response, disease 
regression and diagnosis that has made this protein an attractive therapeutic against chronic diseases. Further, 
the exciting potentials of employing nanotechnology in advancing drug delivery systems, active disease targeting 
and prognosis have also shown some encouraging outcomes. This review focuses on the role of Lf in diagnosing 
infection, cancer, neurological and inflammatory diseases and the recent nanotechnology based strategies. 
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processes. These functions include oxygen transport by red blood cells, 
mitochondrial transport, nucleic acid synthesis and electron transfer 
during cell cycle processes. On the other hand however, excess of 
iron can be detrimental to cells and the dysregulation due to immune 
deficiency or from external agents like microbial infections can lead to 
severe chronic diseases like cancer, sepsis and anaemia [10]. Therefore 
the regulation of iron and its metabolism is essential in conserving 
cellular functions, treating diseases and in the elimination of infections. 
A controversial study by Ward and co-workers [11] demonstrated the 
inability of Lf to regulate iron metabolism in mice. It was reported that 
Lf deficient mice showed normal iron homeostasis in the serum as 
compared to wild type mice. However, since the presence of Lf is only 
increased during inflammation and sepsis, the iron metabolism activity 
of Lf may only come into play during these incidences. 
In a study with six months old infants, radiolabelled breast milk 
showed an increased absorption of iron (49%) as compared to the 
formulated milk (10%). It was suggested that the increased level was 
due to the high concentration of Lf found in human milk [12]. Recently, 
with healthy women, absorption of iron from recombinant human Lf 
(rhLf) produced in rice or from ferrous sulphate showed very similar 
results between the two treatment groups. It was reported that no 
significant difference in absorption was found between heat treated and 
untreated rhLf and also with ferrous sulphate. The equal absorption 
rates proved that iron metabolism using Lf is well utilized in adults 
and the adverse effects such as gastrointestinal discomfort, diarrhoea 
and oxidative damage usually seen with ferrous iron can be avoided 
with the use of Lf [13]. Similarly, a clinical study on pregnant women 
diagnosed with iron deficiency or iron deficiency anaemia was treated 
with 30% iron saturated Lf. It was shown that Lf exhibited significant 
effects on restoring iron and haemoglobin levels in serum. In addition 
with Lf treated women, total iron, ferritin, haemoglobin and red blood 
cell levels were significantly high, while ferrous sulphate and untreated 
women did not shown any change. Further, Lf and ferrous sulphate 
were able to decrease IL-6 activation but this level increased again only 
with the ferrous sulphate, 30 days post-treatment [14]. Taken together 
these results show the benefits of Lf as a modulator of iron metabolism 
and absorption and that the presence of iron could possibly influence 
its multifunctional activities. 
Role of lactoferrin receptors 
Different cells such as gastrointestinal, monocytes/macrophages, 
lymphocytes, platelets, breast epithelial cells, brain cells, osteoblasts, 
chondrocytes and hepatocytes express receptors specific to Lf [8,15]. 
The indication that Lf interacts with cells through receptors was 
first suggested in 1979 by Snick and Masson [16]. An in vitro study 
with mouse peritoneal macrophages reported the distinguished 
internalization of human Lf (hLf) in cells as compared to the uptake of 
Tf. They reported the enhanced iron absorptive activity of Lf, in which 
the Fe present in hLf was efficiently transferred to ferritin molecules in 
the human duodenal mucosa. A possible mechanism for Lf’s improved 
binding affinity was suggested to be due to the nature of Lf to be 
primarily cationic with a high binding affinity to anionic ligands such 
as receptors, glycosaminoglycans and heparin [6, 17-19]. Therefore this 
property enables Lf to bind to a wide array of “Lf putative receptors” 
expressed in different cells and organs and aid with the internalisation 
and absorption of Lf. The low density lipoprotein (LDL) receptor 
related protein-1 (LRP1) and LRP2 (megalin) are two such receptors 
reported to have direct interactions with Lf [20,21]. 
Lactoferrin and LRP
Lf binds to both LRP1 and LRP2 receptors with high affinity [22]. 
Initial studies looking at the different ligands interacting with these 
receptors showed Lf to inhibit the clearance of chylomicron remnants 
known to be efficiently cleared by LRP present in the liver or kidney, 
thus confirming the binding of Lf [21]. In the liver, rapid removal 
of circulatory Lf is mediated by the activity of LRP uptake of Lf in 
hepatocytes via the modulation of the G-protein dependent pathways 
that regulate endocytosis mechanisms [23,24]. Further, blocking with 
receptor-associated protein (RAP), known to inhibit ligands binding to 
LRP, hindered the internalization of Lf by 70% [25]. With osteoblasts 
and chondrocytes, LRP1 was expressed in all bone and cartilage cells 
tested however LRP2 was only expressed in some of the osteoblast cell 
lines. Further cell survival, proliferation and mitogenesis observed with 
Lf treatment was mediated by LRP1 by activating the mitogen activated 
protein kinase (MAPK) pathways and blocking this receptor with RAP 
hindered the endocytosis and signalling transduction activity in cells 
[26,27]. 
Intestinal lactoferrin receptors (LfR)
Another receptor suggested to be specific to Lf, involved with Lf 
internalization and is highly expressed in the small intestine was first 
suggested by Cox et al. [28] in 1979. They reported that incubation 
with hLf, hTf or ovo-Tf on sections of adult small intestines mediated 
the transfer of iron from Lf but not hTf or ovo-Tf. Extensive studies 
examining the tissue localization of LfR has shown that this receptor is 
highly expressed in the intestine, brain cells and the reproductive system 
[15]. Lf internalization studies on a cancerous intestinal epithelial cell 
line, Caco-2, revealed different modes of endocytosis of Lf and Tf 
proteins. It was shown that Lf entered through the apical side and was 
able to localize to the nucleus of cells whereas Tf internalized via the 
basolateral side and remained in the cytoplasm of cells [29]. Similarly, 
more recent studies with Caoc-2 and mouse crypt cells demonstrated 
the distinguished activities of these proteins. LfR expressed in the plasma 
membrane of both type of cells assisted the endocytosis of apo- and 
holo-Lf via the clathrin process. Interestingly, functional studies with 
apo-Lf and holo-Lf showed that apo-Lf induced significant growth of 
these cancerous cells activating the extracellular signal regulated kinase 
(ERK) and the phosphoinositide 3-kinase (PI3K) signalling pathways 
which was down-regulated by blocking LfR. Similar activity however 
was not observed with holo-Lf in which proliferation of Caco-2 and 
crypt cells were inhibited with holo-Lf treatment and activation of ERK 
and P13K cascades were not observed [30,31]. Hence, these unique 
characteristics of LfRs to induce specific and differential mechanisms 
may possibly explain the multiple biological functions exerted by Lf.
Regulation of infections
Lf is a member of the innate immune system and therefore along 
with its iron storage and transportation properties, it also possesses 
antibacterial, antiviral and antiparasitic functions, to name a few. This 
extensive functionality enables Lf to recognise and eradicate a wide 
array of microbial and parasitic strains making it an important part of 
the host defence system. 
Anti-microbial regulation
The antimicrobial activity of Lf is well documented. With microbial 
agents like Escherichia coli, Listeria monocytogenes, Bacillus subtilis, 
Haemophilus influenzae, Klebsiella pneumoniae and Salmonella 
typhimurium, Lf interferes with their metabolism by sequestering 
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the iron required for its growth and proliferation [32,33]. Another 
mechanism, described originally by Arnold et al. [34], reported an 
iron-independent bacteriostatic effect of Lf in which direct binding to 
the surface of infectious agents lead to the destabilization of the cell 
membrane causing its destruction [34]. This bacteriostatic effect of Lf 
is however often masked by some microbes such as Bifidobacterium sp., 
Lactobacillus sp and some forms of viruses. They have the capacity to 
release small sized iron chelators known as siderophores that compete 
and remove iron from Lf thus utilizing it for its survival. Other forms 
have also evolved to express certain specific receptors that bind to Lf 
causing the dissociation of iron by altering the tertiary structure of the 
protein [35]. In vivo studies on mice have demonstrated Lf induced 
rapid eradication of E. coli in kidneys, lungs, liver and spleen, with the 
lungs and kidneys showing the highest level of bacterial killing [36]. 
Moreover, Lf exerted protective effects on mice infected with S. aureus, 
Shigella flexneri and Salmonella spp [37,38]. A recent study by Mosquito 
and colleagues [39] on the effect of bovine Lf (bLf) on S. Typhimurium 
reported Lf to be significantly active in reducing the mortality, signs of 
inflammation and organ necrosis in treated mice groups as compared 
to the untreated. Subsequently, orally administered bLf and rhLf was 
an effective treatment against Helicobacter spp. known to be the cause 
of gastritis, ulcers and stomach cancers [40-42]. 
Bovine Lf (1mg/ml) used in formulas fed to premature infants 
or normal infants were shown to induce the growth of the beneficial 
bacteria Bifidobacterium and inhibited proliferation of Clostridium and 
E. coli [43]. BLf given to patients infected with H. pylori in combination 
with a triple therapy regime completely eradicated the infection from 
78% to 100% [44]. However contradictory to these studies a clinical 
trial with rhLf administered orally over a period of 24 hours to H. pylori 
infected subjects showed no decrease in infection [45]. Furthermore 
a longer treatment regime (5 to 14 days) gave similar outcomes with 
no significant benefits against microbial infections. The combination 
of these results suggests Lf alone may not be an effective therapeutic 
against microbial agents but it may be a significant adjunctive agent to 
be used with other anti-microbial agents. 
Anti-viral regulation
Lf is widely reported to possess anti-viral capabilities. Lf inhibits 
the growth of fatal viruses such as human immunodeficiency virus 
(HIV), rotaviruses, Japanese encephalitis virus (JEV), influenza viruses, 
poliovirus, hepatitis B and C (HBV and HCV) viruses [46,47]. Possible 
mechanisms by which Lf may act is through direct interaction via 
membrane bound protein, iron sequestering or competitive binding to 
host cells, thus preventing viruses or parasites from entering. In viruses 
such as HIV, the transmission to host cells is mediated by binding its 
envelope protein gp120 with dendritic cells which then transmits the 
virus to CD4+ T cells. BLf binds to the adhesion molecule, dendritic 
cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) and prevents HIV from attaching and transmitting to T 
cells [48]. A recent study further confirmed this interaction and linked 
the inhibitory activity of Lf to a Lf-33 peptide expressed in the external 
domain of the protein [49]. Inhibition of HCV was found to be effective 
in cultured hepatocyte cells in which Lf imposed a direct interaction 
with the HCV envelope proteins E1 and E2. Unlike with HBV, pre-
treatment of the virus with Lf inhibited infection but on the other hand 
was ineffective when hepatocytes were pre-treated with Lf [50]. In a 
clinical trial performed on patients suffering from chronic hepatitis, 
bLf treatment (1.8g daily for 12 weeks) showed no difference in virus 
inhibition as compared to the control group, but given at a higher 
concentration (3.6g) followed by a ribavirin and interferon combined 
therapy a significant reduction of HCV was observed [51]. Interaction 
of Lf with heparin sulphate and chondroitin sulphates expressed on the 
cell surface has been demonstrated to inhibit herpes simplex viruses 
[52]. Adenovirus inhibition was reported to be induced by the binding 
of bLf to the viral polypeptides III and IIIa used by viruses to internalize 
into host cells [53] and apoptosis on host cells induced by influenza A 
virus was inhibited by bLf via direct interference of caspase 3 activity 
[54]. 
Anti-parasitic regulation
As an anti-parasitic agent Lf has limited the activity of various 
species like Plasmodium falciparum, Toxoplasma gondii, Entamoeba 
histolytica and Eimeria stiedai. Depletion of iron from Pneumocystis 
carinii and E. histolytica is one of the reported inhibitory mechanisms 
exerted by Lf [55-57]. In addition, apo-Lf has been found to interact 
with the membrane lipids and cholesterol proteins expressed in 
parasites to induce cell death. This is interesting as parasites are known 
to utilize cholesterol/lipids for growth [58]. A recent study further 
demonstrated the capability of Lf peptides, lactoferricin 17–30 and 
lactoferrampin 265–284 to completely eradicate E. histolytica within 24 
hours of treatment [59]. This is further intensified by the ability of Lf to 
induce phagocytosis and destruction of T. cruzi by macrophages [60] 
and to inhibit growth of P. falciparum in erythrocyte [61]. In the case of 
another intestinal parasite, Giardia lamblia, it was observed that Lf and 
N-terminal peptides could effectively kill the parasite [62]. Recently, in 
Peru, a trial for supplementing children diet with bLf to decrease the 
prevalence of diarrhoea showed no significant reduction in diarrhoea 
as compared to control groups but a lower prevalence of giardiasis with 
bLf treatment was observed [63]. 
Another mechanism involves the competitive binding of Lf to the 
membrane molecules heparan sulphates or to LRP receptors expressed 
on host cells. These ligands are usually utilised by Plasmodium spp. 
parasites for cell invasion [64]. Both iron free and iron saturated hLf 
was found to be effective in inhibiting P. falciparum and it was observed 
that a three day pre-incubation of host red blood cells (RBC) prior to 
infection enhances this inhibitory effect [61]. The probable mechanism 
was due to the release of free oxygen radicals leading to the death of the 
parasites. Further studies have shown that Lf inhibits the binding of P. 
falciparum erythrocytes to immobilized chondroitin sulphate receptors 
and CD36 receptors, which are important in the pathogenicity of 
infections [65]. With infections caused by toxoplamosis, intraperitoneal 
and oral administration of Lf was effective in reducing mortality in 
experimental mice [66]. In the case of Pneumocystis carinii, both bovine 
and human Lf could inhibit the cyst and trophozoite stages in vitro [55] 
and could also inhibit infections by microsporidia, another intestinal 
or disseminated parasite common in HIV patients [67].
Diagnosis of infections
The strategy of diagnosing the early onset of diseases and manifesting 
quick, non-invasive and precises prognostics on fatal diseases like 
sepsis, can lead to a significant reduction in mortality and morbidity. 
During normal physiological conditions a relatively low concentration 
of Lf is present in plasma varying from 0.4-2mg/ml. However, during 
inflammation or microbial infections the level of Lf is increased to 
around 200mg/ml [68], which is then significantly reduced with the 
eradication of infection. Lf present in plasma is primarily derived from 
neutrophils. It was found that the levels in healthy patients directly 
correlate with the number of blood neutrophils present. In a study 
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with leukemic and infection prone children it was found that levels 
of Lf in these children were significantly lower than healthy children 
or adults in spite of a higher blood count or unmodified intracellular 
instances [69]. This was similar to results obtained with HIV-1 infected 
patients that had decreased levels of 2.79+1.2 as compared to healthy 
subjects having plasma Lf levels of 4.37 + 0.83 [70]. Hence this protein 
could potentially be used as a biological marker to analyse activity and 
turnover rate of neutrophils sub-sequentially diagnosing the oncome of 
infections and in evaluating subjects that are highly prone to infections. 
Further the shortage of this molecule during complex diseases like HIV 
and cancer could possibly be the reason for disease progression thus 
further confirming the importance of Lf.
Regulation of cancer
Immense developments made over the years on understanding 
the pathophysiology and signalling mechanisms involved in cancer 
has led to the development of potential alternative treatments. 
Standard therapies like radiotherapy, chemotherapy and/or surgery 
not only destroy cancerous cells but have a high tendency to damage 
healthy cells and organs leading to detrimental side effects. Hence to 
overcome these downfalls, the use of natural bioactives as alternative 
therapeutics or as an adjuvant for conventional treatments is rising 
as a possible new avenue in the fight against cancer. Since its first in 
vivo demonstration with solid and metastatic tumours [71] the use of 
Lf as a potential therapeutic for cancer has been highly considered. 
Remarkably, the protective activities of Lf against tumorigenesis and 
metastatic cancers are reported in a wide range of specific organs 
including colon, lung, pancreas, bladder, esophagus and liver, however 
its use as a chemotherapeutic remains to be elucidated. Lf enhances the 
activation of apoptosis in colon, lung and leukemia cancers through the 
up-regulation of caspase 3, caspase 8, Fas receptors, the pro-apoptotic 
Bcl-2 members Bax and Bid [72,73]. It inhibit angiogenesis via vascular 
endothelial growth factor (VEGF) blocking [74] and hinders the growth 
of carcinoma breast, cervical, head and neck cancers at the G1 to S 
transition phase of the cell cycle [75,76]. Furthermore, it increases the 
activation of natural killer (NK) cells and lymphokine-activated killer 
(LAK) cells, up regulates neutrophil activity and enhances macrophage 
cytotoxicity by increasing the production of cytokines and reactive 
oxygen species (ROS) [71]. However, the actual mechanism on how Lf 
promotes signalling in cells remains unclear with theories of nuclear 
factor-kappa B (NF-κB) and MAPK signalling pathways reported to be 
major players [77].
Immunotherapy
The application of immunotherapy as a therapeutic strategy relies 
on the concepts of eliminating cancer and its metastatic counterparts 
primarily through the immune system. It involves grooming the 
immune system to not only specifically target and destroy the affected 
tumour cells but to also sensitize it against metastatic tumour cells 
and against future recurrence of cancer. Other than some of the initial 
immune-modulatory functions of Lf reported almost 30 years ago, it 
also induces the proliferation and differentiation of a range of immune 
cells including lymphocytes, activate polymorphonuclear leukocytes 
(PMN) and improve antibody dependent cytotoxic processes in 
cancers [71,78].
In tumour bearing mice cancer models, bLf administered orally 
revealed its protective effects by enhancing the activation of local 
intestinal mucosa and systemic immune responses. Lf was able to 
stimulate the activation of CD4+ and CD8+ T-lymphocytes and NK 
((asialoGM1+) cells which in turn led to marked inhibition of tumour 
growth and experimental metastasis [46,79,80]. Further Lf increased 
production of caspase-1 protein, interferon IFN-γ and mature 
interleukin (IL)-18 cytokines along with other cytokines including type 
I IFNs, IL-6, IL-7, IL-12 and tumour necrosis factor (TNF)-α [33,78,81-
83]. 
Chemotherapy
As a chemopreventive agent, bLf and its splice variants have shown 
some interesting results. With colon carcinoma 26, a highly metastatic 
cancer implanted in mice and examined for cell colonization in lungs 
revealed bLf fed for 21 days significantly inhibited colonization [79]. 
Similarly, rhLf orally administered to mice implanted with head and 
neck squamous tumours suppressed growth by 75% along with the 
activation of cytotoxic lymphocytes. It was also reported that with 
CD3+ deficient mice, the inhibitory property of rhLf was abrogated, 
further supporting the immunomodulatory function of Lf [84]. 
As an adjuvant agent, rhLf (200 mg/kg) administered orally to 
immunocompetent BALB/c mice in combination with a conventional 
chemotherapeutic drug cis-platimun (5mg/kg) showed significant 
inhibition of head and neck squamous tumour growth. It was shown 
that monotherapy caused an inhibition of 6% and 66% with rhLf and 
cis-platinum respectively, however in combination the inhibition rate 
increased to a significant 79%. It was further shown that rhLf exerted its 
activity through the production of IL-18 and via activation of NK and 
CD8+ T cells [80]. Another significant and interesting study examined 
the activity of iron saturated bLf in augmenting chemotherapy to 
eradicate tumours that are otherwise resistant. Kanwar et al. [33] 
demonstrated 100% iron saturated bLf (Lf+) given to mice infected with 
EL-4 lymphoma completely hindered tumour growth, whereas this 
was only 13-33% with native bLf (~15% iron saturated). Lf+ reduced 
the blood flow to the tumour by 71% and induced an increase in 
tumour apoptosis by 4.2, 5.4 and 4.9 folds when treated with paclitaxel, 
doxorubicin or a combination of both drugs respectively. In addition, 
their study demonstrated that the time Lf+ is administered plays a 
critical role in its inhibitory functions. When given less than two weeks 
before chemotherapy or any time after therapy Lf+ had little or no 
effect on tumour regression, however when given more than two weeks 
before chemotherapy, complete eradication of tumour was reported 
with no recurrence of cancer observed even after mice were returned 
to normal diets. This study further supported the immunomodulatory 
property of Lf in which an enhanced production of Th1 and Th2 
cytokines, IL-4, IL-5, IL-6, IL-10, IL-18, TNF-α and IFN-γ was shown 
along with restored quantities of lymphocytes. It was proposed that Lf+ 
could be used in between routine chemotherapy regimens as it aids in 
destroying resistance tumours and restoring natural defence systems 
[33]. 
Diagnosis of cancer
Lf is famously known as a multifunctional protein primarily 
acting against infections and cancer. However the concept of utilising 
this protein as a tool in diagnosis and detection of cancer remains 
controversial. One of the very first studies suggesting the activity of 
Lf as a marker for cancers was reported by Rossiello and co-workers 
[85]. Their study analysed the presence of three proteins, ferritin, Tf 
and Lf in patients diagnosed with breast carcinomas and found Lf was 
highly expressed in normal breast and benign tissue but was absent in 
cancerous tissue [85]. Since then Lf has been studied as a biological 
marker to detect several forms of cancers including leukemia, colon, 
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breast and cervical carcinomas. In M2 and M4 forms of leukemia, Lf 
was expressed in low concentrations in 12 out of 35 patients suffering 
from acute myeloid leukaemia. Decreased production of Lf was present 
in serum but was absent in the control healthy group. It was suggested 
that the presence of Lf may manifest the dedifferentiated form of 
the normal cell to its cancerous state, as its production is only seen 
in the malignant cells [86]. Similarly, it was shown that the detection 
of Lf concentrations in faecal matter was an effective prognostic for 
confirming colorectal cancer, Crohn’s diseases, colon polyps or 
ulcerative colitis diseases [87]. In a phase II clinical study involving 872 
patients planned to undergo colorectal endoscopy, the expression of 
faecal Lf and haemoglobin was analysed. It was shown that patients 
with colorectal cancer and Crohn’s disease showed a significant 
increase with more than 60% positive for Lf and haemoglobin 
expression [88]. Furthermore, examination of human endometrium 
revealed an overexpression of Lf protein and messenger RNA in 
malignant endometrial adenocarcinomas as compared to the normal 
epithelial cells [89]. Interestingly, in contrast to the above studies, it was 
shown that with certain types of tumours like breast and endocervix 
carcinomas, expression of Lf and its isoforms are significantly down 
regulated as compared to its normal tissue counterparts. It was further 
suggested that this difference in expression among tissues may be linked 
to the activation of steroidal hormones involved in the differentiation 
and growth of cells [90,91]. Although, the strategy of using Lf as a 
definite marker for diagnosing cancer is still undefined, the favourable 
studies reported thus far is opening pathways for it potential use as a 
tool for disease prognosis. 
Nanoparticles as therapeutics
Since its first proposal in the 1970s as a system to effectively delivery 
drugs to specific locations in the body [92,93], treatment of various 
chronic diseases employing nanotechnology has evolved tremendously. 
Various nanomaterials having the capability of providing platforms 
with different chemical properties and biocompatible activities has 
allowed efficient delivery of bioactive agents to target organs. These 
materials present several benefits over conventional approaches, such 
as the ability to efficiently encapsulate several therapeutic modalities 
like proteins, drugs, nucleic acids and peptides. Furthermore, efficient 
conjugation of functionalized agents like ligands, aptamers, antibodies 
or peptides that can target, localize and improve binding affinity 
of nanoparticles (NPs) to specific areas of the body is now feasible. 
Therefore, these properties can further ensure the protection of 
bioactive molecules from degradation via proteases and DNAses and 
enable its prolonged sustainability and long term use without causing 
any severe systemic side effects [94].
Lactoferrin nanoparticles
A major problem with currently used cancer treatments like 
chemotherapy is the inability of drugs to differentiate between 
malignant and healthy cells leading to severe systemic toxicity. The 
distinguishing characteristics of NPs such as the small size (10-200nm), 
large surface-to-volume ratio allowing increased drug encapsulation 
and ease of functionalizing surface properties to accommodate 
multiple ligands that can target tumour specific markers is opening 
new pathways in the search for alternatives to chemotherapy. Since 
its first historical breakthrough in the 1980s with approved clinical 
trials based on polymeric protein conjugates and liposomes, research 
on nanocarrier cancer targeting systems have risen incredibly (Table 
1). Thus utilising Lf as NPs can be a remarkable therapeutic agent, 
combining Lf’s multifunctional properties with the added benefits 
brought by nanotechnology. 
One of the very first studies reported with Lf NPs involved its 
conjugation to DNA encapsulated liposomes targeted to cervical 
cancer Hela cells. It was shown that Lf-liposomes enhanced uptake 
and transfection of genes even at a low concentration of 3µg/ml as 
compared to Tf conjugated liposomes [95]. Another study examined 
the effects of enteric coating on bLf in order to enhance its absorption 
from the intestine of adult rats. The enteric formulation increased 
protection of Lf from gastric enzymes and was transported to the 
lymphatic fluid within 3hours post intragastric administration [96]. 
The possibility of using Lf as a NP to target and treat chronic diseases 
was also proposed by Gupta and Curtis [97]. They demonstrated that 
surface functionalizing superparamagnetic iron oxide NPs with Lf 
and ceruloplasmin interacts with high binding affinity to cell surface 
receptors leading to cell specific particle internalization. Recently, we 
prepared a nanoformulation of iron saturated bovine lactoferrin (Fe-
bLf) for cancer therapy. These nanoformulations were given orally 
in nanodiets prepared using combination of polymers and ceramics. 
Alginate enclosed chitosan coated Fe-bLf or paclitaxel (taxol) NP 
adsorbed onto nanocores of calcium phosphate nanocarriers (AEC-
CP-Fe-bLf NCs or AEC-CP-taxol NCs) were made by combination 
of ionic gelation and nanoprecipitation techniques [98]. These AEC-
CP-Fe-bLf NCs obtained were spherical in morphology and showed 
enhanced anti-cancer efficacy in vitro. Further, these nanocarriers 
were efficiently taken up by the colon cancer (Caco-2) and didn’t affect 
the mucosal integrity during transcytosis. AEC-CP-Fe-bLf NCs were 
supplemented in AIN 93G diet with 1.2% (w/w) of Fe-bLf, by replacing 
casein and fed to mice, in both prevention and treatment xenograft 
colon cancer models. When nanoformulated Fe-bLf diet was given 
orally, as a pre-treatment, one week before Caco-2 cell injections, it 
was found to be highly effective and none of the mice fed with nanodiet 
developed tumours or showed any signs of toxicity. However the mice 
fed with the control AIN-93G diet, showed normal tumour growth. Fe-
bLf loaded nanodiets were also found to help with absorption of iron 
and calcium [98]. 
Brain cancers
The brain is an important organ that needs to be protected from 
unstable conditions caused by hormones, neurotransmitters or from 
foreign organisms such as bacterial or viral infections. The protection 
and seclusion of the brain from these factors is made possible by the 
presence of cells that separates the circulating blood and extracellular 
fluid from the cerebrospinal fluid in the central nervous system. This 
layer, known as the blood brain barrier (BBB) consists of endothelial cells 
that form tightly sealed junctions allowing no direct transendothelial 
passageways of infections originated from bacteria. It also prevents the 
diffusion of macroparticles such as large drug molecules, therapeutic 
nucleic acids and imaging probes [99-101]. As there are so few types of 
drugs that can cross the BBB, delivering drugs to the brain involves a 
number of highly invasive measures. One such technique involves the 
administration of a sugar solution (mannitol) into blood vessels in the 
neck which induces an osmotic reaction causing the endothelial cells 
to shrink [102]. This technique along with several other methods such 
as the use of vasoactive molecules, bradkynin and cereport may force 
the brain to be susceptible to external infections by microbes and even 
from harmful substances in the circulation [103]. 
Since passive transport of drugs is therapeutically ineffective in 
treating brain cancers, active transport through the use of receptors 
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Targeting moiety Platform Tumour model Drug encapsulated Study outcome Ref.
Folate receptor
Dendrimer Oral Methotrexate (MTX)
Enhance localization in tumour and liver tissue. 
Increased MTX antitumour effects and reduced drug 
toxicity
[133]
Liposomes
Oral Doxorubicin (DOX) Internalization was 10 folds higher, significant reduction tumour growth and 30-50% increase in life span [134,135]
Oral Oligo-nucleotides Showed no difference between targeted and nontargeted NP [136]
Magnetite Breast No drug Increased cellular internalization [137]
PSMA antigen PLGA-PEG Prostate Docetaxel Effective uptake (77 fold increase) by cells, inhibited tumour growth and drug toxicity [138,139]
Tranferrin receptor
Gold-PEG Solid Tumour No drug Nps localized to the tumour tissues with decreased amounts in the liver [140]
Liposome Leukemia DOX and Verapamil (Pgp inhibitor) Cytotoxicity was 5.2 time greater that non-targeted NPs [141]
Polymeric Prostate/ Leukemia Cyclodextrin Efficient delivery of drugs to cells [142]
PLGA Prostate Paclitaxel Single dose induce complete inhibition of tumor growth and increased mouse survival rate (80%) [143]
Epidermal
receptors 
HER-2-Liposome Breast No drug No significant difference observed between targeted and nontargeted Nps. [144]
Brain Boron Cellular increase by 8 fold was observed [145]
EGF-gelatin Lung No drug Enhanced uptake in cell in a time and dose dependent manner [146]
αvβ3 integrin
Liposome Pancreas/ Renal Doxorubicin
NP targeted tumour vessel, induced selective apoptosis 
in tumour, caused a 15 fold increase in anti-metastasis 
activity and reduced systemic side effects
[147]
PLGA Liver Paclitaxel/ Doxorubicin Hindered tumour growth and prolonged survival of mice [148]
Melanoma/Colon ATPμ-Raf mutant gene Sustained tumour regression through cell apoptosis activation [149]
Micelles Connective tissue Doxorubicin 30 fold increase of cellular uptake was observed [150]
Vascular cell 
adhesion molecule 
(VCAM-1)
Liposomes Lung No drug 73.1 % localization seen within 30 min with only 30.3% seen with nontargeted NPs [151]
Luteinizing 
hormone releasing 
hormone
Iron oxide Breast No drug
NPs were detected specifically in the cytosol of primary 
and metastatic tumours, whereas unconjugated NPs 
gathered in the liver
[152]
Sigma receptor
Liposomes Lung Survivin siRNA
Targeted NP enhanced delivery, downregulated survivn 
expression, induced cell cytotoxicity, apoptosis and 
chemosensitized cells to cisplatin. In vivo targeted NPs 
localized to specific tumour sites
[137]
Liposomes Prostate Doxorubucin
Increased accumulation, inhibited tumour growth and 
reduced systemic toxicity usually caused by the free 
drug
[153]
Table 1: Targeted nanoparticles for cancer therapy.
seems to be the most sought out way. Several receptors reported to play 
a part in the transport of drugs included Tf, epidermal growth factor 
receptors (EGFR), insulin, low density lipoprotein related receptor 1 
(LRP1), LRP 2 and Diphtheria toxin receptors. Furthermore several 
proteins successful in interacting with these receptors include Lf, Tf, 
melanotransferrin and OX-26 antibody [104]. A study performed by 
Zhang and co-workers [105] showed the conjugation of pegylated 
immunoliposomes with insulin or Tf antibodies was able to effectively 
transport EGFR antisense gene across the BBB and suppress its function 
by 95% [105]. In addition it was also reported that poly (ethylene glycol) 
and polyethylenimine nanogels cross linked with Tf or insulin proteins 
improved the transport and stability of oligonucleotides by almost 15 
folds, with lower toxicity and adverse effects as compared to the free 
nucleotides [106].
Brain Targeting with Lactoferrin
Brain cells including oligodendrocytes, neurons and astrocytes 
express Lf and its up-regulation in parts of the brain is implicated in 
the development of brain disorders including aging, cerebral lesions, 
Alzheimer, Parkinson and Down syndrome diseases [107-109]. 
Although local synthesis of Lf is evident, the large increase observed 
during neurological disorders may imply that Lf might also enter the 
brain through the circulatory system [110]. Hence the uptake and 
transport of Lf from blood through the BBB is mediated specifically 
via dynamic receptor mediated mechanisms and is implied that the 
presence of LRP, expressed in brain endothelial cells is responsible for 
Lf binding and transcytosis [25,111]. 
The active process of Lf transportation can therefore be utilized 
beneficially to generate nano-based drug delivering and brain targeting 
systems that can carry these nanocarriers via similar intracellular 
mechanisms without causing any damage to the BBB. Studies done by 
Huang et al. [112] revealed for the first time the use of Lf as a ligand 
for actively targeting brain capillary endothelial cells and successfully 
delivery nucleotides to the brain. Their study utilized polyamidoamine 
(PAMAM) pegylated dendrimer complexes conjugated to Lf. It was 
shown that the uptake of the Lf/DNA dendrimer NPs were primarily 
mediated through clathrin-dependent and caveolae-mediated 
endocytosis and that the Lf coated NPs were able to localize to the 
central areas of the brain as compared to its uncoated counterparts 
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[100,112]. The Lf conjugated complexes passed through the BBB in a 
time, temperature and concentration dependent manner within the 
first two hours, successfully penetrating to the central areas of the 
brain and distributing within the neuronal cells. Further, a higher 
accumulation was reported with the conjugated NP as compared to the 
uncoated complexes with lower concentrations seen in the liver and 
other organs [112,113]. 
Glioma treatment
Glioma is an aggressive brain tumour with a low mortality of 5% 
in diagnosed patients. The main method of eradicating the cancerous 
growth is through surgery, however the complete removal is not 
always absolute hence the chance of relapse is high [114]. Recently, two 
very similar studies looking at the use of drug loaded, Lf conjugated 
liposomes as a treatment option for glioma was reported. One study 
incorporated the use of a cationic polymersome encapsulated with two 
drugs doxorubicin (DOX) and tetrandrine (TEX) which were further 
conjugated to Lf. DOX is a well-known chemotherapeutic drug and TEX 
blocks calcium associated transporter channels. It was demonstrated 
that Lf conjugation improved the uptake and cytotoxicity in glioma 
cells with an increased rate of 2.3 times more than the unconjugated 
TEX and DOX loaded polymersomes. The conjugated NP effectively 
destroyed glioma cells and significantly impeded the metastatic feature 
of these active cells prolonging the survival time to upto 82% [115]. 
This activity was confirmed in the study performed by Chen et al. [116] 
that demonstrated the enhanced efficiency of Lf conjugated procationic 
liposomes in targeting and treating glioma. Their study showed Lf 
conjugation increased NP uptake in endothelial and glioma cells and 
induced anti-glioma activity in tumour treated mice. It was suggested 
that these NPs internalized through a receptor-mediated pathway and 
caused a significant extension in animal survival rate [116].
Melanoma treatment 
One of the main obstructions faced with the treatment of melanoma 
is its active resistance to chemotherapeutic drugs and radiotherapy. 
Possible mechanisms for this resistance is due to the irregulation of 
apoptosis and DNA, mutations of Ras genes and increased activity 
of transporters such as the ATP binding cassette transporters 
[117]. Recently, a study on murine melanoma cells reported the 
enhanced activity of Lf encapsulated liposomal NPs as a possible 
chemotherapeutic drug. It was shown that the positively charged iron 
free-Lf liposomes were able to protect degradation of the protein and 
the nanoformulation significantly enhanced the internalization into 
cells and cell cytotoxicity and inhibited cell proliferation via cell cycle 
arrest [118].
Edema treatment
The potential use of Lf NPs to enhance its anti-inflammatory effects 
was recently shown in a study performed at the Hoshi University by 
Onishi and co-workers [119,120]. It was considered that a chitosan, 
alginate and calcium NP loaded with Lf would have a high enough 
concentration of Lf to produce an immune response in the body and 
help in the treatment of carrageenan – induced edema. They found that 
the technique used to make the conjugated NPs yielded a concentration 
of 20 – 30% of Lf with an average of 22%. This was three times higher 
than what was produced with other techniques suggesting that the NPs 
contained high concentrations of Lf but remained at an average particle 
size of 1.65µm. They found that when administered to rats suffering 
from carrageenan – induced edema these NPs significantly exhibited 
better suppression and showed a faster recovery from edema as 
compared to the control groups, without Lf or with Lf alone [119,120].
Imaging with lactoferrin
The concept of using radiolabeled hLf as a tool for providing reliable 
diagnostic results during infections through scintigraphy imaging was 
primarily proposed by Welling and his colleagues [121]. Radiolabelling 
hLf peptides with Technetium-99m revealed a significantly high 
binding rate in animals (rabbit and mice) infected with MDR S. 
aureus, Klebsiella pneumoniae or C. albicans as compared to the low 
accumulations seen at sterile inflammatory sites. It was suggested that 
hLf labelled peptides as well as ubiquicidin labelled peptides have the 
potential of being favourable candidates to image site of infections and 
discriminate between microbial induced inflammatory process and 
non-microbial inflamed sites [121-123]. However, due to the known 
limitations of radiolabelled drugs such as toxicity and production 
cost, much work is still required with these peptides before it can be 
effectively used in patients.
Recently, a study demonstrated the encapsulation and delivery 
of fluorescein labelled Lf (FITC-Lf) conjugated to chitosan coated 
alginate/calcium microparticles as an effective intestinal delivery 
system. It was reported that the particles maintained a constant size of 
1-2µm and showed a gradual release of protein over a period of 7 hours. 
Hence it was suggested that since these particles were able to withstand 
and protect the protein from gastric conditions it can be further used 
as a therapeutic or imaging tool to target various diseased sites [124]. 
Magnetic resonance imaging (MRI)
If a cell or a group of cells need to be detected through MRI they are 
usually labelled with magnetic particles either by surface attachment 
or through internalization in cells. Current diagnostic agents such as 
gadolinium cause severe side effects. These include renal dysfunction 
and increased risk of developing nephrogenic systemic fibrosis which 
causes fibrosis of skin, joints, eyes and internal organs. It also has poor 
target-specific biodistribution and rapid exertion [125]. In the 1980s, 
use of super paramagnetic iron oxide NPs (SPIONs) were suggested as 
an alternative to the currently used gadolinium based contrast imaging 
agents [126].
SPIONs exhibit several unique properties. Through in vivo 
testing these particles were shown to be highly sensitive, have 
enhanced biocompatibility and lack toxicity [127,128]. However, a 
key disadvantage of this imaging system is the inability to distinguish 
between malignant and non-malignant tumours. Therefore combining 
these particles to target specific ligands can possibly overcome these 
dilemmas. The use of Lf conjugated to iron oxide particles as a ligand for 
targeting specific cell receptors was first suggested by Gupta and Curtis 
[97] in which Lf conjugated iron oxide NPs were efficiently delivered 
and imaged in human fibroblast cells. Recently, Xie and colleagues 
[129] from the Huazhong University of Science and Technology 
studied the imaging and targeting activity of Lf conjugate iron oxide 
NPs on glioma cancers. They found that these particles were able to 
produce a clearer image as compared to the gadolinium based contrast 
agents which suggests an increased sensitivity and accumulation of NPs 
in glioma cells. It was shown that the Lf conjugated SPIONs had no 
effect on the metabolic activity in glioma infected rats and had a higher 
cellular uptake than that of unconjugated SPIONs. The conjugated NPs 
were effective in differentiating between normal and tumourous brain 
cells and had no observed chronic cytotoxicity. However the MR signal 
Citation: Kanwar JR, Samarasinghe RM, Sehgal R, Kanwar RK (2012) Nano-Lactoferrin in Diagnostic, Imaging and Targeted Delivery for Cancer and 
Infectious Diseases. J Cancer Sci Ther 4: 031-042. doi:10.4172/1948-5956.1000107
Volume 4(3): 031-042 (2012) - 038 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal
degraded within 100 minutes with the Lf-SPIONs as compared to the 
iron oxide particles alone which gave a high intensity even after 140 
minutes. Therefore, these NPs were sensitive to tumour cells and its 
use could be advantageous in the diagnosis of brain disorders as well as 
other carcinogenic tumours. 
Conclusion and Future Directions
There is still without a doubt an unmet necessity to discover a better 
treatment and diagnostic system that can fight cancerous and infection 
diseases. In addition to the currently used chemotherapeutic drugs, 
several promising pharmaceutical agents have entered the market, but 
sadly, like with other conventional drugs they cause adverse side effects 
and exert detrimental effects on normal organs. Hence, with the recent 
advances in technology, NPs may provide opportunities as an effective 
agent that can be used for diagnostic applications, monitoring disease 
progression and eradicating cancerous occurrences. 
Due to the unique physiochemical characteristics shared by NPs, 
these systems can be modified and tuned to encompass cell targeting, 
drug trafficking and imaging systems within a single existence. Hence 
the ideal nanocarrier will specifically target and deliver drug to specific 
sites, minimising systemic toxicity, deliver adequate doses of drugs and 
monitor disease progress efficiently while avoiding invasive imaging 
techniques. Indeed, there are improved therapeutic nanocarriers 
currently established in over 100 clinical trials and various animal 
models that involve the use of a wide array of targeting ligands and 
antibody conjugates. However, in an ideal situation not only is 
targeting, delivering and diagnosis of the cancer important, but it also 
needs to be biocompatible and safe in humans, as this is a common 
problem faced with nonviral therapeutics. Further, NPs need to be 
effective as well as exhibit minimum cytotoxicity when used in the long 
run, as this is a major difficulty faced with most metal based NPs [130]. 
Toxicity that maybe caused by NPs is a crucial factor frequently 
scrutinized in cancer research. The physiochemical characteristics like 
morphology, size, crystalline structure, surface charge and concentration 
of NPs administered during treatments are generally some of the main 
factors leading to particle cytotoxicity [131]. Manipulating size allows 
NPs to reach sites through the leaky vasculature in tumours and gain 
access to areas that are usually unreachable by microparticles. Further 
modifying surface charge can enhance biodistribution and specificity 
of particles. A method that is suggested in several studies is modifying 
these NPs by the attachment of PEG complexes to reduce its toxicity. 
This process reduces toxicity of materials, improve circulation time and 
enhance linking of bioactive compounds however, it can also impede 
with cellular uptake due to the size increase of particles [130]. 
Functionalizing NPs so that they can have longer circulatory half-
lives and entail several targeting ligands such as aptamers, peptides, 
antibodies and imaging probes in one system may also increases the 
efficacy of nanocarriers. These systems will not only improve the 
targeting specificity of diseases, it can show the location of the tumours 
with the use of imaging probes and destroy tumour cells by releasing 
the encapsulated drugs. However, a major setback with this system is 
linking NPs efficiently with all these parameters. The modification with 
these entities may decrease its targeting capability due to a change in 
it physical properties during conjugation and significantly affect its 
binding affinity to the specific biomarkers [132]. Therefore research on 
understanding and optimizing these conditions thus enabling NPs to 
carry these components can result in an intelligent system that can not 
only diagnose diseased cells from normal cells but can be personalized 
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Figure 1: Drug encapsulated transport of multi-ligand targeted nanoparticles. The transport of molecules through the bood brain barrier (BBB) is mediated through 
different mechanism (A). These include (i) transcellular diffusion which depends on the lipophilicity and size of molecules, (ii) transporter protein mediated endocytosis, 
primarily used in the delivery of nutrients, (iii) paracellular diffusion of hydrophilic and small moleculaes through tight juctions of epithelial cells, (iv) receptor mediated 
endocytosis, enabling the transport of various molecules such a genes, proteins and targeted nanoparticles and (v) absorptive transport depending on the surface 
charge of molecules. (B) Nanoparticels trasported through the BBB, targets specific neuronal cells due to the presence of cell specific targeting ligands. Multi-functional 
nanoparticles can be used to detect tumours via MRI [154] (C) and simultaneously induce cell death by releasing chemotherapeutic drugs (D).
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according to the diseases and its severity. Figure 1 shows a schematic 
representation of multi-ligand conjugated NPs targeted at cancerous 
neuronal cells. 
Although the idea of combating all complex and diverse obstacles 
in cancer therapy with a single treatment regime may still be a few 
years away, many prominent nanotechnologist believe that functional 
nano-based systems is the most definite approach in facing these 
issues. Developing and designing NP formulations that address 
multifunctional strategies, have higher specificity, is effective and 
safe can therefore be effectively used in diagnostic and personalized 
therapies.
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